CUBE TECH FAIR 2017: Experience the 4th Industrial Revolution

10 - 12 May 2017, Berlin, Germany.
The new annual CUBE TECH FAIR will showcase the pioneering and disruptive innovations and technologies that the top team of connectors and partners have hand picked globally. Interact with B2B startups, corporate executives, institutions and thought leaders that have been enabled by CUBE throughout the year.

CUBE TECH FAIR gives you fast and direct access to the most relevant B2B startup for your business:

  • Get premier access to B2B startups and more than 500 CEOs from B2B startups of all sizes and industries.
  • Experience and access innovations and disruptive technologies as well as outstanding projects.
  • Get connected to expertise and knowledge across different industries from digital health to manufacturing.

Hello Startups! Ready to boost your business?
Want to show the most relevant executives what you've got and engage in partnerships that help you scale up fast? Be part of the CUBE TECH FAIR 2017 in Berlin:

  • Meet 2,000+ business leaders, entrepreneurs, executives, investors, technology influencers, startup ecosystem leaders, institutions, and other brilliant minds.
  • Get premiere access to the industry and to their distribution channels. Show them how you can revolutionize the industry 4.0.
  • Opportunity for scaling up fast and short time to market through partnership with corporates.
  • Get globally connected to corporate expertise and knowledge across different industries from digital health to manufacturing.

Brilliant minds get their ticket now.

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

Hint: The faster you buy your ticket, the cheaper it is.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...